The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Homocysteine – from disease biomarker to disease prevention
Abstract
We have reviewed the literature and have identified more than 100 diseases or conditions that are associated with raised concentrations of plasma total homocysteine. The commonest associations are with cardiovascular diseases and diseases of the central nervous system, but a large number of developmental and age‐related conditions are also associated. Few other disease biomarkers have so many associations. The clinical importance of these associations becomes especially relevant if lowering plasma total homocysteine by B vitamin treatment can prevent disease and so improve health. Five diseases can at least in part be prevented by lowering total homocysteine: neural tube defects, impaired childhood cognition, macular degeneration, primary stroke, and cognitive impairment in the elderly. We conclude from our review that total homocysteine values in adults of 10 μmol/L or below are probably safe, but that values of 11 μmol/L or above may justify intervention. Homocysteine is more than a disease biomarker: it is a guide for the prevention of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Emdin, C. A., Khera, A. V., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2017.17219 · Cited by 3,637
Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study
(1991) · The Lancet · doi:10.1016/0140-6736(91)90133-a · Cited by 3,472
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
Seshadri, S., Beiser, A., Selhub, J., Jacques, P. F., Rosenberg, I. H., D'Agostino, R. B., Wilson, P. W. F., & Wolf, P. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011613 · Cited by 3,237
Vitamin Status and Intake as Primary Determinants of Homocysteinemia in an Elderly Population
Selhub, J. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510220049033 · Cited by 1,972
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
Wald, D. S., Law, M., & Morris, J. K. (2002) · BMJ · doi:10.1136/bmj.325.7374.1202 · Cited by 1,946
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
Ks, M. (1969) · PubMed Central · Cited by 1,803
Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease
Nygård, O., Nordrehaug, J. E., Refsum, H., Ueland, P. M., Farstad, M., & Vollset, S. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370403 · Cited by 1,756
Self-citationPlasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project
Graham, I. M. (1997) · JAMA · doi:10.1001/jama.1997.03540460039030 · Cited by 1,738
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa060900 · Cited by 1,729
Cited by
Normal‐tension glaucoma: Current concepts and approaches‐A review
Leung, D. Y. L., & Tham, C. C. (2022) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.14043 · Cited by 99
Davies, M. J. (2025) · Redox Biochemistry and Chemistry · doi:10.1016/j.rbc.2025.100052 · Cited by 11
Metadata
- Authors
- Smith, A. D., & Refsum, H.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 2021-04-06
- Volume
- 290
- Issue
- 4
- Pages
- 826-854
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W3134243068
- Cited by
- 261
- References
- 161
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Homocysteine – from disease biomarker to disease prevention. https://app.cochat.ai/papers/10.1111/joim.13279
- The paper
- Smith, A. D., & Refsum, H. (2021). Homocysteine – from disease biomarker to disease prevention. Journal of Internal Medicine. https://doi.org/10.1111/joim.13279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.